Spectre Intelligence GTM brain

category

market profile

• text: Spectre describes a trading firm and research operation, not a publicly offered SaaS product; external capital allocation terms are not established.
• text: Other quantitative firms apply AI to trading research and compete for capital, data, talent and market opportunities.
• text: Evidence for independent audited results of autonomous AI trading remains limited, making risk controls and track record important diligence topics.

personas

• title: Potential institutional capital allocator
  pains:

  • Needs an independently verifiable performance and risk history before allocating to a new manager.
  • Must assess whether model-driven strategies remain robust across changing markets.
• title: Biotech or semiconductor domain expert
  pains:

  • Specialist information is complex and fast moving.
  • A research partnership needs clear scope and appropriate information controls.
• title: AI research candidate
  pains:

  • Wants a real-world environment to test agent learning under uncertainty.
  • Needs credible research infrastructure, data and feedback loops.

icp

• text: Potential capital partners are sophisticated investors able to evaluate early-stage systematic trading risk; public materials do not establish an open fund or minimum allocation.
• text: Potential research partners include experts in semiconductor and biotechnology markets; firm size and geography are not specified.

message pillars

• text: Present trading as an evolutionary learning problem.
• text: Emphasize survival as a precondition for learning.
• text: Frame agent development around competition and feedback.
• text: Acknowledge shared investment risk.

objections

• objection: What proves the strategy works beyond backtests?
  response: Provide independently verifiable live performance, risk metrics and appropriate disclosures when available; no audited record is established here.
• objection: How are losses and model failures controlled?
  response: Discuss governance, limits and human oversight in diligence rather than promise outcomes.
• objection: Is this an investable product or a proprietary trading operation?
  response: Clarify whether outside capital is accepted, eligibility, fees and structure directly with the firm.

competitors

• name: Contrarian Technology
  website: https://contek.io/
  why: Quantitative firm using AI and scientific research for systematic trading.
• name: 42
  website: https://www.42.com/about
  why: AI research company applying autonomous research to quantitative trading.
• name: WorldQuant
  website: https://www.reuters.com/technology/ai-drives-surge-worldquants-university-quant-contest-participation-2025-10-06/
  why: Systematic investment firm developing agentic research systems.

influencers

• name: Michelle Li
  url: https://www.ycombinator.com/founders/michelle-li
  why: Co-founder and CEO who writes the firm's research philosophy.

keywords

• AI quantitative trading firm
• autonomous trading agents
• AI hedge fund
• systematic biotech investing
• semiconductor quantitative trading
• AI investment research
• agentic trading research

voice

• introspective
• technical
• candid about uncertainty

signals

• text: A sophisticated investor is evaluating emerging systematic managers and can conduct full risk diligence.
• text: A domain expert works on semiconductor or biotech markets and is interested in research collaboration.

pricing

motion

channels

• research blog
• LinkedIn
• YC network

confidence

Founders

• name: Michelle Li
  title: Founder/CEO
  role: CEO
  bio: Co-founder and CEO at Spectre Intelligence, on leave from Harvard (I studied Economics & Biology and was originally class of '27). Previous research across generative protein language models, bacteriophages, CRISPR Cas9, and more. ISEF grand award winner, RSI and STS scholar.
• name: Joshua Zyzak
  title: Founder/CTO
  role: CTO
  bio: Founder at Spectre Capital, CS and EE at Harvard, researched deep-RL controllers for quadruped robots and multimodal LLM-robotics